NAD+ Information & Coordination for Licensed U.S. Clinics
Nicotinamide adenine dinucleotide, commonly referred to as NAD or NAD+, is a naturally occurring coenzyme involved in cellular metabolic processes.
FDA currently lists Nicotinamide Adenine Dinucleotide (NAD) in Category 1 of its section 503A bulk-drug-substance framework, meaning the nominated substance remains under evaluation. Category 1 status is not FDA approval and does not mean the substance has been finally included on the 503A Bulks List.
The regulatory position under section 503B is different. FDA stated in a January 2026 warning letter that NAD+ did not qualify for the section 503B bulk-substance exemptions described in that case because NAD+ was not on the 503B Bulks List and was not being used to compound a drug on FDA’s shortage list.
Phoenix Meds Inc. supports licensed healthcare organizations with credential review, documentation, publicly available regulatory information, and administrative coordination.
We are not a pharmacy, medical practice, manufacturer, prescriber, compounder, or dispensing entity.
What Clinics Should Know About NAD+
NAD+ appears in wellness and longevity settings, including discussions of injectable preparations. Those uses should not be presented on this page as established FDA-approved indications.
The regulatory pathway also matters.
For traditional pharmacy compounding under section 503A, FDA currently places NAD in Category 1 while its evaluation remains underway. The Category 1 designation reflects an interim FDA enforcement policy when applicable conditions are met; it should not be represented as FDA approval or blanket authorization to compound or dispense NAD+.
A clinic should therefore distinguish between the identity of the bulk substance, the type of compounding entity, the proposed preparation, and the requirements applicable to the particular situation.
503A and 503B Require Separate Review
FDA maintains separate bulk-substance frameworks for traditional pharmacy compounding under section 503A and outsourcing facilities operating under section 503B.
FDA currently lists Nicotinamide Adenine Dinucleotide (NAD) in Category 1 of its 503A framework. Category 1 means the nominated substance remains under evaluation and does not constitute FDA approval or final inclusion on the 503A Bulks List.
FDA’s 503B materials separately list Beta-Nicotinamide Adenine Dinucleotide in Category 1 of the agency’s interim 503B framework. Category 1 status under section 503B likewise does not constitute FDA approval or final inclusion on the 503B Bulks List.
Exact bulk-substance identity matters. In a January 2026 warning letter to GenoGenix LLC, FDA determined that the NAD+ used by that particular outsourcing facility did not qualify for the section 503B exemptions and was not eligible for FDA’s interim Category 1 policy.
Phoenix therefore does not assume that a product described commercially as “NAD” or “NAD+” qualifies for a particular compounding pathway based on its name alone. The specific substance, documentation, compounding entity, and applicable federal and state requirements require separate review.
Sterile Compounding and Ingredient Quality
NAD+ also has an important FDA safety history.
FDA has specifically warned compounders about the use of food-grade NAD+ ingredients in sterile injectable preparations. FDA states that ingredients identified as food grade are not suitable for sterile drug compounding without appropriate processing because microbial or endotoxin contamination can create patient risk.
FDA has also received adverse-event reports associated with injectable NAD+ products, including severe chills, shaking, vomiting, and fatigue, with some patients requiring medical treatment. The agency noted that the reported reactions were consistent with excessive endotoxin exposure.
In a January 2026 enforcement action involving an outsourcing facility, FDA reported that testing of an unopened vial from an implicated NAD+ lot found excessive bacterial endotoxin.
For Phoenix, this means ingredient sourcing, sterile-processing claims, testing, and product-quality assurances should remain the responsibility of the entity actually manufacturing or compounding the preparation.
Why Product Specific Documentation Matters
“NAD+ 1000 mg” by itself does not establish the complete identity, regulatory status, concentration, dosage form, storage conditions, sterility assurance, or suitability of a particular preparation.
Those details depend on the actual product and the entity responsible for preparing it.
Phoenix should therefore not publish universal specifications such as:
- “1000 mg per vial” as a standard product;
- IV or IM availability;
- refrigerated storage at 2°C–8°C;
- standardized cold-chain requirements;
- fixed administration instructions; or
- guaranteed lot, sterility, potency, or endotoxin documentation.
Those are product-specific matters that should come from the responsible licensed pharmaceutical party.
How Phoenix Meds Supports Licensed Clinics
Phoenix’s role is administrative.
We may assist licensed healthcare organizations with professional credential review, organization of available documentation, review of publicly available FDA and licensing information, and administrative communication concerning documentation.
Where information supplied by another party is incomplete or inconsistent, Phoenix may help identify the issue so the clinic can direct the question to the responsible pharmacy, manufacturer, regulatory professional, or other licensed party.
Phoenix’s administrative review is not FDA approval, pharmacy accreditation, clinical advice, or a legal opinion.
Safety and Documentation Considerations
Compounded drugs are not reviewed by FDA for safety, effectiveness, or quality before marketing in the same manner as FDA-approved drugs.
NAD+ sterile preparations also require particular attention to ingredient suitability and contamination risk. FDA has specifically warned about inappropriate food-grade NAD+ ingredients being used for sterile compounding and has documented adverse events potentially associated with excessive endotoxin exposure.
Phoenix does not manufacture, compound, test, dispense, store, ship, or take custody of NAD+ preparations.
We do not certify a product’s purity, potency, sterility, endotoxin level, authenticity, safety, clinical suitability, or compliance.
NAD+ Administrative Coordination for Licensed Clinics
Clinic Verification
Professional and facility credentials may be reviewed as part of Phoenix’s administrative process.
Documentation Review
Licensed Parties
Prescribing, compounding, dispensing, distribution, testing, storage, shipping, and other regulated pharmaceutical activities remain with the parties legally authorized and responsible for performing them.
Frequently Asked Questions
Does Category 1 status mean NAD+ is FDA approved?
No. FDA Category 1 status relates to the agency’s interim compounding policy and is not FDA approval. FDA has also taken enforcement action against specific NAD+ drug products marketed without approved applications.
What is NAD+'s current 503A status?
NAD is currently listed in 503A Category 1 — Bulk Drug Substances Under Evaluation. The designation reflects an interim FDA policy while evaluation remains ongoing; it is not final inclusion on the 503A Bulks List.
Does NAD+ automatically qualify for compounding under section 503B?
No. FDA maintains specific requirements for bulk substances used by outsourcing facilities. FDA’s 503B Category 1 materials include Beta-Nicotinamide Adenine Dinucleotide, but Category 1 is an interim policy status rather than FDA approval or final inclusion on the 503B Bulks List. The exact bulk substance and the circumstances of compounding must be evaluated against the applicable requirements.
Has FDA raised concerns about injectable NAD+?
Yes. FDA has warned about inappropriate food-grade NAD+ ingredients being used to compound sterile products and has received adverse-event reports consistent with excessive endotoxin exposure.
Does Phoenix Meds provide NAD+ dosing or administration protocols?
No. Phoenix does not establish dosing, infusion protocols, routes of administration, treatment schedules, or patient-specific clinical recommendations.
Does Phoenix Meds guarantee sterility or product quality?
No. Phoenix does not manufacture or test NAD+ preparations and cannot certify their purity, potency, sterility, endotoxin levels, safety, or suitability.
What can Phoenix Meds help with?
Our work is administrative and may include professional credential review, documentation organization, publicly available regulatory information, and administrative communication concerning documentation.
Important Notice
Phoenix Meds Inc. provides administrative coordination, documentation, and compliance-focused support for licensed healthcare organizations.
We are not a pharmacy, medical practice, manufacturer, outsourcing facility, compounder, prescriber, or dispensing entity.
This page is intended for professional informational purposes. It does not represent NAD+ as an FDA-approved treatment, establish clinical effectiveness for wellness or longevity uses, or establish that a particular preparation or compounding pathway is available or permitted.
Regulatory References
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the FD&C Act
- Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act
- FDA Reminds Compounders to Use Ingredients Suitable for Sterile Compounding
- GenoGenix LLC — FDA Warning Letter, January 20, 2026
- Thrive Health Solutions — FDA Warning Letter, February 9, 2026